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Sensing nutrient availability is essential for appro-
priate cellular growth, and mTORC1 is a major regu-
lator of this process. Mechanisms causing mTORC1
activation are, however, complex and diverse. We
report here an additional important step in the activa-
tion of mTORC1, which regulates the efflux of amino
acids from lysosomes into the cytoplasm. This pro-
cess requires DRAM-1, which binds the membrane
carrier protein SCAMP3 and the amino acid trans-
porters SLC1A5 and LAT1, directing them to lyso-
somes and permitting efficient mTORC1 activation.
Consequently, we show that loss of DRAM-1 also im-
pacts pathways regulated by mTORC1, including
insulin signaling, glycemic balance, and adipocyte
differentiation. Interestingly, although DRAM-1 can
promote autophagy, this effect on mTORC1 is auto-
phagy independent, and autophagy only becomes
important for mTORC1 activation when DRAM-1 is
deleted. These findings provide important insights
intomTORC1 activation and highlight the importance
of DRAM-1 in growth control, metabolic homeosta-
sis, and differentiation.
INTRODUCTION
Cell growth and homeostasis are critically dependent on nutrient
availability for biosynthesis. Under fed conditions, cells utilize
external nutrients; in periods of starvation, cells activate macro-
autophagy (hereafter autophagy) that produces biosynthetic
precursors and energy through the lysosomal breakdown of in-
ternal macromolecules (Dunn, 1990; Takeshige et al., 1992).
The interplay between use of external and internal precursors
is tightly controlled by mechanisms that sense and respond to
nutrient availability. A major factor in this regard is the mTORC1
complex, which is activated by amino acids and contains theMolecular Cell 76, 1–14, O
This is an open access article under the CC BY-Nserine/threonine kinase mTOR (Goberdhan et al., 2016). When
activated, mTOR phosphorylates substrates that promote pro-
tein translation, such as ribosomal protein S6 kinase-1 (S6K1)
and eukaryotic translation initiation factor 4 binding protein 1
(4E-BP1) (Hara et al., 1998). At the same time, mTOR phos-
phorylates Unc-51-like autophagy-activating kinase 1 (ULK1),
causing inhibition of autophagy (Jung et al., 2009). Reciprocal
effects occur under starved conditions when mTORC1 is
repressed (Egan et al., 2011; Gwinn et al., 2008). Changes in
the activation of mTORC1 also affect insulin sensitivity by modu-
lating the activation of the serine/threonine kinase AKT down-
stream of insulin receptors. This then influences the ability of
cells to respond to changes in serum glucose and also the differ-
entiation and deposition of adipose tissue.
Due to its impactonmultiple cellularprocesses, theactivationof
mTORC1 is highly regulated, and several mechanisms have been
described (Goberdhanet al., 2016).Many studies haveshown that
mTORC1 senses amino acids at the lysosome, and in nutrient-
replete conditions, mTORC1 is localized at lysosome mem-
branes—an interaction that is lost upon starvation (Sancak et al.,
2010). In this context, mTORC1 is thought to initiate amino acids
sensing fromwithin the lysosomebywhat hasbeen termedan ‘‘in-
side-out’’ mechanism involving the vacuolar ATPase (Zoncu et al.,
2011). It has also been reported, however, that amino acids and in
particular leucine—themain activating amino acid for mTORC1—
are sensed in the cytoplasm via leucyl-tRNA synthetase and
SESTRIN-2 (Han et al., 2012; Parmigiani et al., 2014; Wolfson
et al., 2016). In this study, we report that DRAM-1 is a component
of the nutrient-sensing system that links lysosomal and cyto-
plasmic sensing by facilitating amino acid transport across the
lysosomal membrane. Moreover, we show that loss of DRAM-1
leads to an inhibition of mTORC1 activation, which affects meta-
bolic signaling pathways and organismal health.RESULTS
DRAM1 Promotes mTORC1 Activation Independent of
Autophagy
We previously identified DRAM-1 as a lysosomal membrane
protein that promotes autophagy downstream of p53 (Crightonctober 3, 2019 ª 2019 The Author(s). Published by Elsevier Inc. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. DRAM1 Stimulates Amino-Acid-
Induced mTOR Activation
(A) Saos2 TetOn-DRAM1-myc-his-tagged cells
were, where indicated, treated with doxycycline
(Dox) for 24 h and then starved for 3 h in EBSS
before treatment with EBSS containing essential
amino acids for the indicated times. mTOR activa-
tion was evaluated by measuring phospho-S6 ki-
nase levels by western blot. Total S6 kinase levels
or actin were used as loading controls. DRAM1
expression was detected using an anti-Myc-tag
antibody.
(B) Dram1flox/flox MEF expressing Cre recombinase
(/) or a control vector (fl/fl) was starved for 3 h in
EBSS prior to 20 min in EBSS containing 0.8 mM
leucine. mTOR activation was evaluated by
measuring phospho-S6 kinase, phospho-4E-BP1
levels by western blot. S6K, 4E-BP1, and ERK2
were used as loading controls.
(C) Flow cytometry analysis of cell size of
Dram1flox/flox MEF expressing Cre recombinase
(/) or a control vector (fl/fl) grown under control
or starvation conditions for 3 h. FSC, forward
scatter. Boxplot and whiskers: 1–99 percentile. Bar
represents median. *p < 0.05.
(D) Cell proliferation of Dram1flox/flox MEF express-
ing Cre recombinase (/) or a control vector (fl/fl).
Equal cell numbers were split on day 0 in complete
DMEM. From day 2, cells were harvested daily and
counted using Innovatis cell counter. Result shown
is representative of 3 independent experiments.
Data are mean ± SD. *p < 0.05.
(E) Dram1flox/flox MEF expressing Cre recombinase
enzyme (/) or a control vector (fl/fl) were starved
for 3 h in EBSS containing glutamine prior to DMEM
treatment for the indicated times. Repression of
autophagy by mTOR activation was assessed by
western blot of LC3B (I and II) and phospho-S6
kinase. ERK2 was used as a loading control.
Result shown is representative of 3 independent
experiments.
See also Figures S1 and S2.
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(2019), https://doi.org/10.1016/j.molcel.2019.07.021et al., 2006). Because autophagy and mTORC1 activity are con-
nected (Tan and Miyamoto, 2016), we questioned whether
DRAM-1 also affects mTORC1. To examine this, we starved
and re-fed Saos2-TetOn-DRAM1 cells that had been incubated
in either the absence or presence of doxycycline (Dox) to induce
DRAM-1 levels. Analysis of S6K1 phosphorylation, an estab-
lished readout of mTORC1 activity (Burnett et al., 1998), upon
starvation in Earle’s balanced salt solution (EBSS) followed by
addition of amino acids, clearly showed that higher levels of
DRAM-1 facilitated mTORC1 activation at all time points
analyzed (Figure 1A). To test whether this effect was a facet of
endogenous DRAM-1, we isolated mouse embryonic fibroblasts
(MEFs) from embryonic day 13.5 (E13.5) Dram-1flox/flox mice and
infected these cells with a retrovirus expressing Cre recombi-
nase or ‘‘empty’’ retroviral vector as control (Figure S1A).2 Molecular Cell 76, 1–14, October 3, 2019Starvation of these cells for 3 h followed
by addition of leucine for 20 min caused
a marked increase in S6K1 phosphoryla-tion that was essentially absent in Dram-1/ cells (Figure 1B).
Decreased phosphorylation of another mTORC1 substrate,
4E-BP1, was also observed, which together with decreased
S6K1 phosphorylation indicates a critical role for DRAM1 in the
activation of mTORC1 (Figure 1B). Importantly, these effects
were not observed upon Cre infection of wild-type MEFs (Fig-
ure S1B). Consistent with a defect in the ability to activate
mTORC1, DRAM1-null cells have decreased growth rate and
size when compared to controls (Figures 1C and 1D) and have
a diminished ability to repress autophagy upon re-feeding—as
assessed by lower levels of the lipidated form of LC3 (LC3-II),
a marker of autophagosomes (Figures 1E and S1C; Klionsky
et al., 2016).
Due to DRAM-1’s previously described role in autophagy
(Crighton et al., 2006), and because autophagy can increase
Figure 2. DRAM1 Interacts with LAT1 and SLC1A5 Amino Acid Transporters to Stimulate mTOR Activation
(A) Saos2 TetOn-DRAM1 cells treated with or without doxycycline for 24 h before incubation in full DMEM or EBSS for 3 h. Cells were harvested and lysed prior to
immunoprecipitation of DRAM1 using anti-Myc-tag antibody. Immunoblotting from total protein extracts (INPUT) or elutions (IP DRAM1) was undertaken to
detect SLC7A5 (LAT1), SLC1A5, DRAM1 (Myc tag), and ERK2 (loading control). A representative result from at least 3 independent experiments is shown.
(B) Saos2 TetOn-DRAM1 cells expressing the indicated short hairpin RNA (shRNA) constructs were grown in the presence or absence of doxycycline for 24 h.
Myc-tagged proteins were immunoprecipitated and samples analyzed bywestern blotting to detect DRAM-1 (Myc tag), SLC7A5, SLC1A5, or SLC3A2. ERK2was
used as a loading control.
(C) Quantifications of SLC7A5 and SLC1A5 bound to DRAM1 from 3 independent experiments. Data are mean ± SEM. *p < 0.05.
(D–F) Experiments were performed using Dram1flox/flox MEF expressing Cre recombinase (/) or a control vector (fl/fl).
(D) Cells were starved in EBSS with, where indicated, 2 mM glutamine for 3 h before incubation in EBSS containing 0.8 mM leucine for 20 min.
(E) Cells were starved in EBSS containing glutamine for 3 h before incubation for 20 min in EBSS containing 0.8 mM leucine, 10 mM D-phenylalanine, and
25 mg/mL cycloheximide as indicated.
(legend continued on next page)
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(2019), https://doi.org/10.1016/j.molcel.2019.07.021amino acid levels and mTORC1 activity (Yu et al., 2010), we first
considered that DRAM-1may affect mTORC1 via its role in auto-
phagy. As a result, we generated mice hemizygous for Dram-1
that also contain two floxed alleles of Atg7—an essential auto-
phagy gene (Komatsu et al., 2005; Tanida et al., 1999). Inter-
crossing these mice resulted in animals with floxed Atg7 alleles,
which were also either wild-type, hemizygous, or null for Dram-1
(Figure S2A). Examination of MEFs from these mice revealed,
consistent with our previous observations, that loss of DRAM-1
severely impaired the ability to activate mTORC1, as assessed
by S6K1 phosphorylation (Figure S2B). These cells also had a
diminished ability to repress autophagy and a decreased growth
rate (Figures S2C and S2D). Treatment with bafilomycin A1, an
inhibitor of the lysosomal vacuolar ATPase (Bowman et al.,
1988), also reduced leucine’s ability to activate mTORC1 in
Dram1+/+ Atg7flox/flox cells (Figure S2E), underscoring the impor-
tance of lysosomal function in this response. However, and in
contrast, infection of Dram1+/+ Atg7flox/flox cells with a retrovirus
expressing Cre to delete Atg7 did not diminish mTORC1 activa-
tion (Figures S2F and S2G). In fact, loss of autophagy only
reduced leucine-mediated mTORC1 activation when Dram-1
was also deleted (Figures S2G and S2H). This therefore shows
that DRAM-1 has a role in mTORC1 activation that is indepen-
dent of autophagy and that autophagy only serves as a back-
up for mTORC1 activation when this DRAM-1/mTORC1 axis is
impaired.
DRAM1 Promotes mTORC1 Activation by Binding the
Amino Acid Transporters LAT1 and SLC1A5
To gain insight into DRAM-1’s role in mTORC1 activation, we
searched for DRAM-1-interacting proteins among factors en-
riched from HeLa cells containing exogenous DRAM-1 linked
to a tandem-affinity purification (TAP) tag (Gloeckner et al.,
2007). Based on the frequency of peptide identification by
mass spectrometry and our interest in proteins linked to nutrient
sensing and autophagy, we were drawn to the amino acid trans-
porters SLC3A2, SLC1A5, and SLC7A5 (Figure S3A). These
transporters were previously linked to mTORC1 activation
through their action at the plasma membrane, where SLC1A5
(also known as ASCT2) imports glutamine to facilitate the activity
of a complex between SLC3A2 and SLC7A5 (also known, and
hereafter collectively referred to, as LAT1 for large neutral amino
acid transporter), which imports leucine and reciprocally exports
glutamine (Nicklin et al., 2009). To confirm our TAP tag results in
a different system, we performed immunoprecipitation in Saos2-
TetOn-DRAM1 cells. Upon immunoprecipitation of DRAM-1, an
interaction could clearly be seen with SLC1A5 (Figure 2A). An
interaction could also be detected between DRAM-1 and both
SLC7A5, indicating an interaction with LAT1 (Figure 2A). More-
over, immunoprecipitation of DRAM-1 mutants lacking regions
from the N or C terminus revealed that LAT1 binds to DRAM-
1’s C terminus (Figures S3B and S3C). To test whether the inter-
action with these transporters was inter-dependent, we(F) Cells were starved for 3 h in EBSS containing glutamine alone or suppleme
containing 0.8 mM leucine alone or supplemented with 100 nM rapamycin for 20
(D–F) mTOR activation was detected bymeasuring phospho-S6 kinase levels by w
See also Figure S3.
4 Molecular Cell 76, 1–14, October 3, 2019repeated these immunoprecipitations in cells where we had
knocked down either SLC7A5 or SLC1A5. This revealed that
interaction between DRAM-1 and SLC7A5 was not diminished
by knockdown of SLC1A5 and vice versa (Figures 2B and 2C),
indicating that DRAM-1 interacts with the two amino acid trans-
porters independently.
We were interested to know whether the effect of DRAM-1 on
mTORC1 activation was related to SLC1A5 and LAT1 binding.
Because pre-loading with glutamine can enhance the ability of
LAT1 to import leucine (Nicklin et al., 2009), we first tested
whether glutamine pre-loading could affect mTORC1 activation
in Dram-1 flox/flox and Dram-1/ cells. This clearly showed, in
line with previous studies, that glutamine pre-loading enhances
leucine’s effects on mTORC1, but again, little activation of
mTORC1 was observed in DRAM1-null cells (Figure 2D). We
next directly assessed the involvement of LAT1 and SLC1A5 in
this system by respectively treating cells with D-phenylalanine
(D-Phe) (Yanagida et al., 2001) and L-g-glutamyl-p-nitroanilide
(g-GPNA) (Esslinger et al., 2005), two well-characterized inhibi-
tors of leucine and glutamine uptake by these transporters. In
both cases, the ability of glutamine pre-loading followed by addi-
tion of leucine to activatemTORC1was abolished by these inhib-
itors, showing a clear role for these transporters in the activation
of mTORC1 in these cells and underscoring DRAM-1’s role in
this process (Figures 2E and 2F).
DRAM-1 Directs LAT1 and SLC1A5 to Lysosome
Membranes to Invoke Amino Acid Efflux
Our findings caused us to consider that DRAM-1 loss may
reduce mTORC1 activation by reducing the ability of SLC1A5/
LAT1 to import leucine at the cell membrane. However, analysis
of intracellular leucine bymass spectrometry in cells incubated in
either EBSS or EBSS plus glutamine for 3 h followed by incuba-
tion in EBSS plus leucine indicated this was not the case (Fig-
ure 3A). Therefore, we considered that DRAM-1 may be promot-
ing mTORC1 activation via SLC1A5/LAT1 at a different cellular
location. As DRAM-1 is predominantly a lysosomal protein and
because mTORC1 is localized at lysosomes when active, we
considered that DRAM-1 may facilitate lysosomal localization
of SLC1A5/LAT1 to lysosomes, enabling transfer of amino acids
into this organelle. To test this, we performed three different
experiments. First, we examined SLC1A5 localization by immu-
nofluorescence in TetOn-DRAM1 cells, which showed that
DRAM-1 expression causes a re-localization of a proportion of
SLC1A5 to lysosomes (Figures 3B and 3C). Second, we gener-
ated a construct that expresses SLC3A2 linked C-terminally to
mRFP and GFP (SLC3A2-RFP-GFP). In this context, based on
the known membrane orientation of SLC3A2, GFP and mRFP
should be located in the acidic lumen if this transporter is
directed to the lysosomal membrane. As a result, because fluo-
rescence from GFP, but not mRFP, is acid labile (Kimura et al.,
2007), if DRAM-1 directs a proportion of these transporters
to the lysosome, the relative fluorescent intensities betweennted with L-ɣ-glutamyl-p-nitroanilide (ɣ-GPNA) before treatment with EBSS
min.
estern blotting. Total S6 kinase and ERK2 levels were used as loading controls.
(legend on next page)
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(2019), https://doi.org/10.1016/j.molcel.2019.07.021mRFP and GFP should change if DRAM-1 is deleted. Indeed,
when analyzed by flow cytometry, the level of GFP relative to
mRFP was indeed lower in Dram1flox/flox cells compared with
DRAM1-null cells (Figure S4A). In addition, when analyzed by
fluorescent microscopy, a significant reduction in the amount
of this construct was observed at lysosomes in DRAM1-null cells
compared to controls (Figures S4B–S4D). In contrast to these re-
sults, no DRAM1-dependent difference in GFP/mRFP intensity
was observed using a construct in which SLC3A2 was fused
N-terminally to red fluorescent protein (RFP) and GFP (RFP-
GFP-SLC3A2), which results in the fluorophores being on the
outside of the lysosome membrane (Figure S4A). In a final
approach, we purified lysosomes using a construct expressing
LAMP1-RFP-FLAG (Zoncu et al., 2011). This resulted in clear
enrichment for SLC1A5/LAT1 as well as LC3-II and LAMP2
(known autolysosomal/lysosomal proteins) in the lysosomal frac-
tion, and expression of DRAM-1 increased the amount of
SLC1A5 and LAT1 in this cellular fraction (Figures 3D–3F and
S4E). Collectively, these data show that DRAM-1 directs a pro-
portion of SLC1A5 and LAT1 to the lysosome membrane.
If DRAM-1 brings a proportion of SLC1A5/LAT1 to the lyso-
somal membrane to facilitate leucine import, then DRAM-1
should not be required for mTORC1 activation in response to
methyl-leucine—an analog of leucine that diffusees across
membranes without the aid of transporters and accumulate in ly-
sosomes, where it is de-esterified to yield leucine (Reeves,
1979). Analysis of methyl-leucine uptake by mass spectrometry
showed it was indeed efficiently taken up by cells, and this, as
observed with leucine in Figure 3A, was not affected by
DRAM-1 deletion (Figure 3G). Surprisingly, however, mTORC1
activation by methyl-leucine was still dependent on DRAM-1
(Figure 3H). Moreover, methyl-leucine increased the lysosomal
localization of SLC1A5 and SLC7A5 (Figures 3D–3F), and the
activation of mTORC1 observed in Dram-1+/+ (Dram1fl/fl on fig-
ures) cells was blocked by inhibition of LAT1 with D-Phe or byFigure 3. DRAM1 Drives LAT1 and SLC1A5 Amino Acid Transporters to
(A) Dram1flox/flox MEFs expressing Cre recombinase (/) or a control vector (fl/fl
0.8 mM leucine in EBSS for 20 min. Intracellular leucine was determined by liqui
(B) Saos TetOn-DRAM1-myc-his cells overexpressing V5-tagged SLC1A5 were g
fixed and stained for LAMP2 and SLC1A5(V5-tag). Scale bars represent 50 mm.
(C) Quantification of colocalization coefficients of LAMP2with SLC1A5-V5-tagged
at least 25 cells).
(D) Saos2 TetOn-DRAM1 cells expressing LAMP1-RFP-FLAG23were induced w
to 20-min treatment with 0.8 mMmethyl-leucine ester. Lysosome-enriched fractio
(E and F) Quantification of 3 independent experiments was determined using I
normalized to LAMP2 and compared to non-induced starved DRAM1 cells. *p <
(G) Intracellular leucine (Leu) or methyl leucine ester (CH3-Leu) were analyzed as
EBSS supplemented with 0.8 mM methyl-leucine ester for 20 min.
(H and I) Dram1flox/flox MEF expressing Cre recombinase (/) or a control vector
treatment with EBSS supplemented with 0.8 mM leucine or 0.8 mM methyl leuci
indicated for 20 min. mTOR activation was detected by measuring phospho-S6
(J) Amino acid transporters SLC1A5 or SLC7A5 were downregulated using siRNA
(fl/fl). mTOR activation was detected by measuring phospho-S6 kinase levels b
treated with 0.8 mM methyl leucine ester for 20 min. ERK2 was used as a loadin
(K) Metabolites from lysosomal fractions were analyzed for intralysosomal leucine
3 independent experiments are presented as the amount of lysosomal leucine me
with methyl-leucine ester. *p < 0.05.
For micrographs, scale bars represent 50 mm. (A and G) Data are mean ± SD. (C
See also Figure S4.
6 Molecular Cell 76, 1–14, October 3, 2019small interfering RNA (siRNA)-mediated knockdown of SLC1A5
or SLC7A5 (Figures 3I, 3J, S4F, and S4G). These RNAi data
also serve to corroborate our data using D-Phe and g-GPNA in
Figures 2E and 2F, underscoring the importance of these trans-
porters in this response (Figures 2E, 2F, 3I, 3J, and S4G).
In light of these results, we considered instead that DRAM-1
may facilitate lysosomal localization of SLC1A5 and LAT1,
enabling amino acid efflux from lysosomes, and it is this efflux
that is required for mTORC1 activation. If this was correct,
expression of DRAM-1 should not only increase the lysosomal
localization of SLC1A5/LAT1, but this should also decrease in-
tralysosomal levels of leucine and maybe also glutamine. To
test this, we analyzed amino acid levels in purified lysosomal
fractions, which clearly showed decreased levels of leucine
and glutamine in DRAM1-expressing cells that had been treated
with methyl-leucine (Figures 3K, S4E, and S4H). These findings
are therefore consistent with a model in which DRAM-1 facili-
tates mTORC1 activation by directing a proportion of SLC1A5/
LAT1 to the lysosomal membrane, where these transporters pro-
mote amino acid efflux in a manner independent of autophagy.
We were naturally interested to understand the mechanism by
which DRAM-1 re-localizes SLC1A5/LAT1 to lysosomes. We
found that the ability of DRAM-1 to re-localize SLC1A5 is
blocked by short-term treatment with the translation inhibitors
cycloheximide and anisomycin (Figure 4A). This did not, how-
ever, affect total SLC1A5 levels (Figure 4B), indicating that
DRAM-1 somehow captures a proportion of newly synthesized
transporter and restricts its traffic to the plasma membrane.
With this theory in mind, we looked again at the other proteins
we had found that bind to DRAM-1 (Figure S3A). Among these
proteins was secretory carrier membrane protein 3 (SCAMP3),
which is involved in membrane traffic events, including traffic
to the plasma membrane. Subsequent studies not only
confirmed that DRAM-1 binds SCAMP3 (Figure 4C) but also
that DRAM-1 causes enhanced localization of SCAMP3 withLysosomes, which Export Amino Acids and Induce mTOR Activation
) were starved for 3 h in EBSS with or without glutamine before treatment with
d chromatography-mass spectrometry (LC-MS) analysis.
rown for 24 h in the presence or absence of doxycycline (1 mg/mL). Cells were
in Saos TetOn-DRAM1 cells treated or not with doxycycline for 24 h (average of
ith or without doxycycline for 24 h. Cells were then starved for 3 h in EBSS prior
ns were analyzed by western blot for levels of LAMP2, SLC1A5, and SLC7A5.
mageJ. Results represent the relative amounts of SLC7A5 (E) or SLC1A5 (F)
0.05.
described in (A) in cells that were starved in EBSS for 3 h before treatment with
(fl/fl) cells were starved in the absence or presence of glutamine for 3 h before
ne ester (H) or 0.8 mM methyl leucine ester and 10 mM D-phenylalanine (I) as
kinase levels by western blot. ERK2 was used as a loading control.
s in Dram1flox/flox MEFs expressing Cre recombinase (/) or a control vector
y western blot after cells were starved 3 h in EBSS containing glutamine and
g control.
content using high-performance liquid chromatography (HPLC)-MS. Results of
asured for each condition and normalized to non-induced DRAM1 cells treated
–F and K) Data are mean ± SEM.
(legend on next page)
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re-localization of SCAMP3wasmechanistically connected to the
lysosomal re-localization of the amino acid transporters, we
examined DRAM-1’s effects in cells where SCAMP3 had been
silenced by RNAi. This completely impaired the ability of
DRAM-1 to re-localize SLC1A5 to lysosomes and also abolished
the ability to activate mTORC1 with leucine (Figures 4E–4G).
These findings therefore support a hypothesis in which
DRAM-1 binds and retains SCAMP3 and a proportion of newly
synthesized SLC1A5/LAT1 at lysosomes.
DRAM-1 Controls Insulin Signaling
Changes in mTORC1 activity can have a negative impact on
insulin signaling, because mTORC1 signaling drives negative
feedback on insulin receptor substrate 1 (IRS-1) through inhibi-
tory phosphorylation (Harrington et al., 2004; Tremblay and
Marette, 2001; Um et al., 2004). This causes reduced phospha-
tidylinositol 3-kinase (PI3K) flux and a resultant decrease in the
phosphorylation of AKT at T308—the site phosphorylated by
PDK1 in response to insulin (Alessi et al., 1997). We were there-
fore interested to knowwhether DRAM-1 affects insulin signaling
and found that DRAM1-null cells exhibit markedly increased and
sustained AKT phosphorylation over a range of insulin concen-
trations (Figures 5A, 5B, and S5). In addition, and in line with
our observations connecting DRAM-1 and mTORC1 activation,
we found that the differential levels of AKT phosphorylation be-
tween Dram-1+/+ (fl/fl) and Dram-1/ cells could be largely
normalized by treatment with rapamycin, an inhibitor of mTORC1
(Brown et al., 1994; Sabatini et al., 1994), but was unaffected by
deletion of Atg7, indicating an autophagy-independent link
between DRAM-1, mTORC1, and insulin signaling (Figures 5C–
5E). It is important to note that, in these experiments, the prin-
cipal signal for mTORC1 activation, as measured by S6K phos-
phorylation, is excess insulin in insulin-treated cells. As a result,
the comparative levels of S6K phosphorylation at T-389 between
DRAM-1+/+ (fl/fl) and DRAM-1/ cells is different than that
observed when re-feeding amino acids is used as a stimulus
for mTORC1, as shown in Figures 1, 2, 3, and 4.
Inspired by our observations that loss of DRAM-1 promotes in-
sulin signaling, we wanted to know whether these effects cause
changes in glucose or insulin tolerance in vivo. To test this, wild-Figure 4. DRAM1 Interacts with SCAMP3 to Drive SLC1A5 and LAT1 to
(A) Saos TetOn-DRAM1-myc-his cells overexpressing V5-tagged SLC1A5 were
treated for 4 h with cycloheximide (100 mg/mL) or anisomycin (10 mg/mL). Cells w
(B) Saos2 TetOn-DRAM1-myc-his cells overexpressing V5-tagged SLC1A5 were,
cycloheximide (100 mg/mL) or anisomycin (10 mg/mL). SLC1A5 expression was de
levels were detected using an anti-Myc tag antibody. Actin was used as a loadin
(C) Saos2 TetOn-DRAM-1 cells treated with or without doxycycline for 24 h wer
Immunoblotting from total protein extracts (INPUT) or elutions (IP DRAM-1) was
(D) Saos Tet-On-DRAM1-myc-his cells overexpressing V5-tagged SLC1A5 were
fixed in 4% paraformaldehyde and stained for SCAMP3, DRAM1 (Myc-tag), and
(E) SCAMP3 was downregulated using siRNA in Saos-2 TetOn-DRAM1-myc-his
absence of doxycycline (1 mg/mL). Cells were fixed in 4% paraformaldehyde and
(F) Colocalization coefficients were determined using Zeiss Zen Black software (
(G) SCAMP3 was downregulated using siRNA in Saos TetOn-DRAM1-myc-his ce
for 24 h, and then starved for 3 h in EBSS before treatment with EBSS containing le
kinase and phospho-S6 levels by western blot. Levels of total S6 kinase, S6, and a
anti-Myc-tag antibody, and SCAMP3 knockdown was measured using an anti- S
8 Molecular Cell 76, 1–14, October 3, 2019type and Dram-1/ mice were maintained on a high-fat diet
(HFD) and subjected to a glucose tolerance test by oral gavage
of glucose or to an insulin tolerance test following intraperitoneal
injection of insulin. In line with enhanced insulin signaling in the
absence of DRAM-1, this revealed that Dram-1/ mice are
able to mitigate hyperglycemia at a faster rate than wild-type
animals (Figure 6A). In our insulin tolerance tests, we observed
that wild-type andDram-1/mice fed a HFD did not display dif-
ferences in glycemia regulation when compared to mice fed a
standard chow diet (Figures S6A and S6B). This lack of differ-
ences could be due to an excess of insulin injected, which in cells
abolishes differences observed in AKT signaling (Figure S5).
Interestingly, differences in insulin tolerance were revealed
when mice were subjected to rapamycin injections, a treatment
already described to further promote type 2 diabetes in mice.
Indeed, and consistent with our previous observations, wild-
type mice became almost insensitive to insulin upon mTOR
inhibition and Dram-1/ mice were not affected (Figures S6A
and S6B). Over a longer period of time, this ability to tolerate
and adjust hyperglycemic conditions at a faster rate was accom-
panied by reduced animal weight, lower levels of subcutaneous
and epididymal fat, reduced liver weight, and lower serum levels
of adiponectin—an indicator of the extent of adipose tissue in the
whole animal (Figures 6B–6E and S6C). As before, treatment
with rapamycin showed that these results were connected to
the activity of mTORC1. Interestingly, analysis of fat from
Dram-1/ mice revealed no significant changes in adipocyte
density or size (Figures S6D and S6E), indicating that DRAM-1
loss may instead be affecting the signaling and differentiation
state within adipose tissue. In line with this and consistent with
our previous observations, we observed that adipose tissue
from Dram-1/ mice, when compared to wild-type mice, had
increased levels of phospho-AKT S473, a readout of the full acti-
vation of AKT (Figures 6F and S6I), and phospho-AKT-S473 and
-T308 levels were similar in mice fed a HFD (Figures S6F, S6G,
S6I, and S6J). Notably, and in accordance with our in vitro
results (Figures 5C–5E), phosphorylation of AKT-T308 is only
increased by rapamycin treatment in wild-type mice (Figures
S6G and S6J).
Interestingly, and consistent with previous studies (Laplante
et al., 2012), adipocytes show no differences in phospho-S6KLysosome Membranes
grown for 24 h in the presence or absence of doxycycline (1 mg/mL) and then
ere fixed in 4% paraformaldehyde and stained for Lamp2 and V5.
where indicated, treated with doxycycline for 24 h and then treated for 4 h with
tected using an anti-V5 antibody: a short and long exposure is shown. DRAM-1
g control
e lysed prior to immunoprecipitation of DRAM-1 using anti-Myc-tag antibody.
undertaken to detect SCAMP3, DRAM-1 (Myc tag), and ERK2.
grown for 24 h in the presence or absence of doxycycline (1 mg/mL). Cells were
SLC1A5 (V5-tag).
cells overexpressing V5-tagged SLC1A5, grown for 24 h in the presence or
stained for SLC1A5(V5-tag) and LAMP2.
average of at least 25 cells). Data are mean ± SEM.
lls overexpressing V5-tagged SLC1A5, then, where indicated, treated with Dox
ucine for 20min. mTORC1 activation was evaluated bymeasuring phospho-S6
ctin were used as loading controls. DRAM1 expression was detected using an
CAMP3 antibody.
Figure 5. DRAM1 Promotes Insulin Resistance through mTOR Activation
(A) Dram1flox/flox MEFs expressing Cre recombinase (/) or a control vector (fl/fl) were grown overnight in serum-depleted DMEM prior to treatment with 5 nM
insulin for 15 min. Western blots for phospho-AKT T308, phospho-S6 kinase, phospho-S6 ribosomal protein, and insulin receptor substrate 1 (IRS1) were
performed to evaluate activation of the insulin pathway. ERK2 was used as a loading control.
(B) Similar experiments to those in (A) were performed to evaluate the kinetics of insulin pathway activation following different insulin exposure times.
(C) Cells were treated as in (A) except that, prior to insulin treatment, cells were incubated with or without 100 nM rapamycin for 4 h. Western blots for phospho-
AKT T308, phospho-S6 kinase, phospho-S6 ribosomal protein, total AKT, total S6 kinase, and total S6 ribosomal protein were performed to evaluate outcomes of
mTOR inhibition on cellular insulin sensitivities.
(D) Atg7flox/flox Dram1/ or Atg7flox/flox Dram1+/+ MEFs were treated as in (C) in order to evaluate the role of autophagy in DRAM1-induced insulin resistance.
(E) Quantification of 3 independent experiments described in (D). Phospho-AKT T308 levels were normalized to total AKT levels. Data aremean ± SEM. **p < 0.01.
See also Figure S5.
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(2019), https://doi.org/10.1016/j.molcel.2019.07.021levels and phospho-IRS1 levels are significantly decreased
in DRAM-1-null mice fed a HFD, when compared to similarly
fed wild-type animals (Figures 6G, 6H, and S6H–S6K).
Altogether, these results: (1) point to the existence of a
compensatory mechanism that Dram-1/ mice establish toovercome their innate defect in mTORC1 activation, (2)
demonstrate that DRAM-1 is connected to the PI3K/AKT/
mTOR pathway in mice, and (3) reveal a specific role of
DRAM-1 during adipogenesis, as confirmed by the following
results.Molecular Cell 76, 1–14, October 3, 2019 9
Figure 6. DRAM1-Null Mice Are Less Prone to
HFD-Induced Glucose Intolerance
(A) Glucose tolerance test was performed on mice
fed a high-fat diet for 22 weeks. Blood glucose levels
were measured at different time points following
glucose administration (10 mice per group).
(B) Mouse weights were measured weekly during
the course of the HFD experiment. Results are
mean ± SEM for each time point (10mice per group).
(C and D) Subcutaneous (C) and epididymal adipose
tissues (D) were weighed at the end of the HFD
experiment.
(E) Plasma adiponectin levels were measured for
each mouse using ELISA.
(F) AKT activation levels in epididymal adipose tis-
sues were evaluated by immunohistochemistry
(IHC) staining for phospho-AKT S473. Quantifica-
tions of at least 5 different mouse adipose tissues
per group (5 pictures per mouse) were performed
using Adobe Photoshop CS5.1 software.
(G and H) S6 kinase activation (G) and S636/639
IRS1 phosphorylation (H) in epididymal adipose
tissues were evaluated by western blots for phos-
pho-S6 kinase and phospho-S636/639 IRS1.
Quantifications of 10 different mouse adipose tis-
sues per group were performed using ImageJ.
Where indicated, rapamycin (RAPA) was adminis-
trated (4 mg/kg) by intraperitoneal injection twice a
week for the duration of the experiment.
All data are mean ± SEM. *p < 0.05; **p < 0.01; ***p <
0.001. n.s., non-significant.
See also Figure S6.
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Our evidence suggested that DRAM-1 controls adipocyte
signaling and differentiation and that this is associated with
changes in mTORC1 activity. This idea is consistent with previ-
ous reports that have indicated that mTORC1 regulates this
process (Martin et al., 2015). The role of mTORC1 is, however,
reportedly complex, whereby the kinase complex promotes dif-
ferentiation from precursor cells to pre-adipocytes but inhibits
differentiation from pre-adipocytes to adipocytes (Laplante
et al., 2012). As a result, although loss of DRAM-1 has an overall10 Molecular Cell 76, 1–14, October 3, 2019negative impact on the accumulation of
adipose tissue (Figure 6), we were inter-
ested to understand how DRAM-1 might
regulate the differentiation of adipocytes
when cultured in isolation and, in particular,
how DRAM-1 might affect the later stages
of differentiation from pre-adipocytes to
adipocytes. If this is again potentially con-
nected to the regulation of mTORC1, we
would predict DRAM-1, like mTORC1,
would negatively affect this terminal stage.
To test this, we utilized the 3T3-L1 cell line,
which is a well-characterized model of
differentiation from pre-adipocytes (Green
and Kehinde, 1975). Our initial analysis
supported our hypothesis when we found
that DRAM-1 expression is increased in3T3-L1 cells when induced to differentiate from pre-adipocytes
to adipocytes (Figure S7A). We therefore decided to disrupt
DRAM-1 in this line using CRISPR/Cas9 gene editing to assess
the role of DRAM-1 in the later stages of adipocyte differentiation
(Figure S7B). Similar to what is observed upon mTORC1 inhibi-
tion (Laplante et al., 2012), differentiation of these cells indeed
showed that loss of DRAM-1 potentiates differentiation from
pre-adipocytes to adipocytes, as assessed by increased
oil red O staining (Figures 7A and 7B). This differentiation
was accompanied by increased levels of adiponectin and
Figure 7. DRAM1 Impairs 3T3-L1 Pre-adipocyte Differentiation
3T3-L1 pre-adipocytes infected with 2 different guide sequences targeting Dram1 or 2 non-targeting control guides (NTC) were left undifferentiated or differ-
entiated for 8 days in differentiation media containing various amounts of troglitazone (0–4 mM).
(A) Cellular neutral lipid contents were shown following oil red O staining.
(B) Staining was quantified by eluting oil red O in isopropanol and measuring optical densities at a wavelength of 500 nm. Results are the mean staining of the
2 different Dram1 CRISPR cell lines for each condition normalized to the average staining of the 2 different NTC cell lines. Results are from 3 independent
experiments.
(C) qPCR analysis showing Adiponectin expression levels in 3T3-L1 NTC or Dram1 CRISPR cells grown with regular or differentiation medium containing the
indicated concentration of troglitazone.
(legend continued on next page)
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another marker of terminal adipocyte differentiation (Figures
7C–7E). In addition, differentiation in DRAM-1-null cells was
associated with increased AKT phosphorylation at T308 and
decreased p-IRS1 levels, without changes in phospho-S6K (Fig-
ures 7D, 7F–7H, and S7C). This indicates that these effects are
associated with differences in mTORC1 activity and insulin
signaling as we had observed and are similar to those observed
by Laplante et al. (2012) in their study looking at the effects of
DEPTOR on differentiation from pre-adipocytes.
When taken together, our results identify DRAM-1 as a critical
component in mTORC1 activation by mediating amino acid
efflux from lysosomes. As a consequence, loss of DRAM-1
impairs mTORC1 activity, leading to changes in insulin sensitivity
and adipocyte differentiation, suggesting a key role for DRAM-1
in the control of obesity and diabetic control.
DISCUSSION
We report here that DRAM-1 is involved in the activation of
mTORC1. As mTORC1 activity represses autophagy (Rabanal-
Ruiz et al., 2017), it could initially be considered that these find-
ings are at oddswith our previous report showing that DRAM-1 is
a positive regulator of autophagy downstream of p53 (Crighton
et al., 2006). One distinct difference in our studies, however, is
that we showed that DRAM-1 positively affects autophagic flux
when elevated by p53, which importantly also occurs in the
context of p53-mediated activation of other target genes
involved in an autophagic response (Kenzelmann Broz et al.,
2013). In this study, we show that DRAM-1’s effects on mTORC1
occur in a different context—in either p53-null cells and/or in
cells with basal (non-p53-stimulated) levels of DRAM-1. We
acknowledge, however, that it could still be the case that the
facilitation of autophagy by DRAM-1 could lead to an increase
in intralysosomal amino acids and subsequent activation of
mTORC1. However, we found that mTORC1 activation is an
autophagy-independent function of DRAM-1 and that auto-
phagy is only critically important for mTORC1 activation in the
absence of DRAM-1. These results therefore highlight both
context-specific effects/roles of DRAM-1 as well as the relative
importance/contribution of internally derived amino acids for
mTORC1 activation.
In light of these results, we searched for DRAM-1 binding
factors that may be connected to mTORC1 activation. This
led to the finding that the amino acid transporters LAT-1 and
SLC1A5 bind DRAM-1 and that cells with depleted levels of
LAT1 or SLC1A5 show markedly diminished amino-acid-
induced mTORC1 activation. Initially, we considered that
DRAM-1, a lysosomal protein, may bring these transporters(D) Pre-adipocyte differentiation efficiency was evaluated by western blots directe
controls.
(E) Quantification of PPARɣ levels measured from 3 independent experiments w
(F) Quantification of phospho-AKT levels measured from 3 independent experim
(G) mTOR activation was evaluated by western blotting for phospho-S636/639 IR
(H) Quantification of phospho-S636/639 IRS1 levels measured from 3 independe
(B, C, E, F, and H) Data are mean ± SEM. *p < 0.05; **p < 0.01.
See also Figure S7.
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into lysosomes—a step which at the time was undefined. We
found, however, that this was not the case, and recent studies
have now shown that a different lysosomal membrane protein,
LAPTM4b, directs LAT-1 to the lysosomal membrane to facili-
tate amino acid import (Milkereit et al., 2015). In contrast to
our initial thoughts, we found that DRAM-1, through its interac-
tion with SCAMP3, directs LAT-1 and SLC1A5 to lysosomal
membranes, where, instead of facilitating amino acid import,
they facilitate amino acid export to the cytoplasm. The impor-
tance of this step is exemplified by the fact that increased
DRAM-1 levels reduce intralysosomal leucine and that
DRAM-1 is required for mTORC1 activation in cells that have
been treated with esterified leucine, which can enter lysosomes
freely, but upon cleavage to leucine requires transporter activity
for lysosomal export (Reeves, 1979).
Recent studies have implicated SLC38A9 as a factor required
for amino acid export across the lysosomemembrane, leading to
mTORC1 activation. Initially, SLC38A9 was considered an argi-
nine sensor (Rebsamen et al., 2015; Wang et al., 2015), but
recent in vitro assays have shown that SLC38A9 also has leucine
transporter activity (Wyant et al., 2017). It is therefore natural to
consider that there may be interplay between the activities of
SLC38A9, LAT-1, and SLC1A5 in cells. For example, as LAT-1
is considered the principal leucine transporter at the plasma
membrane, could it be possible that SLC38A9 is required for
LAT-1 to export leucine? Or, conversely, are LAT-1 and
SLC1A5 required for SLC38A9 function? Future studies in this
area would certainly be insightful.
We also report that DRAM-1 is involved in several biological
functions where mTORC1 has been shown to be a regulator.
We show that DRAM-1 is important for insulin signaling and
that, in vivo, this has implications for glucose tolerance in mice
on a high-fat diet. Our finding, however, that loss of DRAM-1 pro-
motes differentiation from pre-adipocytes to adipocytes at first
hand seems incongruous with previous reports showing a posi-
tive role for mTORC1 in adipocyte differentiation. For example, it
has been reported that treatment with rapamycin can inhibit
adipocyte differentiation and knockout of TSC1/TSC2 can pro-
mote adipocyte differentiation (Yeh et al., 1995; Zhang et al.,
2009). However, it is important to note that, unlike rapamycin,
loss of DRAM-1 does not completely block mTORC1 but impairs
its activation. In line with this ‘‘partial’’ inhibition of mTORC1, we
found that DRAM-1 loss in pre-adipocytes does not affect the
phosphorylation of S6K, but it does reduce phosphorylation of
IRS-1 at S636/639—the site phosphorylated by mTORC1 (Tzat-
sos, 2009; Tzatsos and Kandror, 2006). This partial (or selective)
inhibition of mTORC1 is not without precedent. Laplante et al.
(2012) showed that overexpression of the mTOR inhibitord against phospho-AKT T308 and PPARɣ. AKT and ERK2were used as loading
as performed using ImageJ.
ents was performed using ImageJ.
S1 in Dram1 CRISPR 3T3-L1 cells or NTC CRISPR cells.
nt experiments was performed using ImageJ.
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while having no apparent effects on the phosphorylation of S6K.
These changes in IRS-1 phosphorylation caused by loss of
DRAM-1 or DEPTOR overexpression led to changes in AKT
phosphorylation and upregulation of PPARg—events that
promote differentiation from pre-adipocytes to adipocytes.
Despite the similarities between the role of DEPTOR and
DRAM-1 on mTORC1 activity during differentiation to adipo-
cytes, we have to acknowledge that the partial effects on
mTORC1 activity caused by deletion of DRAM-1 may not be
the only mechanism affected by DRAM-1 loss in this context.
As yet unknown mechanisms may contribute to the differentia-
tion process in a manner either dependent or independent of
the regulation of mTORC1.
When taken together, our findings identify and characterize
DRAM-1 as a critical component involved inmTORC1 activation.
The impact of DRAM-1 loss not only impacts the biochemical
readouts of mTORC1 activation but also markedly affects bio-
logical processes connected to mTORC1 and reveals potential
roles for DRAM-1 in insulin sensitivity, obesity, and diabetic
control.STAR+METHODS
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Antibodies (anti-)
Myc tag Millipore cat# 05-724; RRID: AB_309938
ERK2 Santa Cruz biotechnology cat# sc-154; RRID: AB_2141292
Flag-Tag Sigma-Aldrich cat# 3165; RRID: AB_259529
LAMP2 (aka CD107b) BD PharMingen cat# 555803; RRID: AB_396137
SLC3A2 (aka CD98hc) Santa Cruz biotechnology cat# sc-9160; RRID: AB_638288
SLC1A5 (aka ASCT2) Cell Signaling cat# 5345; RRID: AB_10621427
SLC7A5 (aka LAT1) Cell Signaling cat# 5347; RRID: AB_10695104
LC3B Cell Signaling cat# 2775; RRID: AB_515950
Phospho S6 Ribosomal protein Cell Signaling cat# 4858; RRID: AB_516156
S6 Ribosomal protein Cell Signaling cat# 2317; RRID: AB_2238583
Phospho 4E-BP1 Cell Signaling cat# 2855; RRID: AB_560835
4E-BP1 Cell Signaling cat# 9644; RRID: AB_2097841
Atg7 Cell Signaling cat# 8558; RRID: AB_10831194
Phospho AKT (S473) Cell Signaling cat# 9271; RRID: AB_329825
Phospho AKT (T308) Cell Signaling cat# 4056; RRID: AB_331163
AKT Cell Signaling cat# 9272; RRID: AB_329827
PPARg Cell Signaling cat# 2430; RRID: AB_823599
Anti-mouse IgG HRP-linked Cell Signaling cat# 7076S; RRID: AB_330924
Anti-rabbit IgG HRP-linked Cell Signaling cat# 7074S; RRID: AB_2099233
Phospho-IRS-1 Cell Signaling cat# 2388; RRIS: AB_330339
Phospho p70 S6 Kinase Cell Signaling cat# 9234; RRID: AB_2269804
p70 S6 Kinase Cell Signaling cat# 2708; RRID: AB_390722
ARF6 Cell Signaling cat# 3546; RRID: AB_2058484
V5-Tag Cell Signaling cat# 13202; RRID: AB_2687461
LAMP2 Alexa Fluor 488 conjugate Thermo Fisher Scientific MA1-205-A488; RRID: AB_2688309
Myc Tag Alexa Fluor 488 Millipore cat#16-224; RRID: AB_442399
Scamp3 Proteintech 26888-1-AP; RRID: AB_2810962
V5-Tag DyLight 650 conjugate Thermo Fisher Scientific MA5-15253-D650; RRID: AB_2537642
VPS35 Abcam ab97545; RRID: AB_10696107
Chemicals, Peptides, and Recombinant Proteins
D-Phenylalanine Sigma-Aldrich cat# P1751
L-Leucine methyl ester hydrochloride Sigma-Aldrich cat# L1002
L-g-glutamyl-p-nitoanilide Sigma-Aldrich cat# G6133
L-Leucine Sigma-Aldrich cat# L8000
cycloheximide Sigma-Aldrich cat# C4859
puromycin Sigma-Aldrich cat# P9620
polybrene Sigma-Aldrich cat# H9268
doxycyclin Sigma-Aldrich cat# D9891
Protein A Sepharose beads Sigma-Aldrich cat# P9424
Anti-FLAG M2 Magnetic Beads Sigma-Aldrich cat# M8823
bicinchonic acid solution Sigma-Aldrich cat# B9643
Copper (II) sulfate solution Sigma-Aldrich cat# C2284
troglitazone Sigma-Aldrich cat# T2573
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insulin Sigma-Aldrich cat# I9278
IBMX Sigma-Aldrich cat# I5879
dexamethasone Sigma-Aldrich cat# D4902
Oil Red O solution Sigma-Aldrich cat# O1391
Earle’s Balanced Salt Solution Sigma-Aldrich cat# E2888
Fetal Bovin Serum Thermo Fisher Scientific cat# 10270-106
penicillin/streptomycin Thermo Fisher Scientific cat# 15140-122
glutamine Thermo Fisher Scientific cat# 25030-024
accutase Thermo Fisher Scientific cat# A11105-01
trypsin Thermo Fisher Scientific cat# 15090-046
Dulbecco’s Modified Eagle Medium Thermo Fisher Scientific cat# 21969-035
50X MEM amino acid solution Thermo Fisher Scientific cat# 11130-036
LysoTracker Deep Red Thermo Fisher Scientific cat# L12492
HALT protease and phosphatase
inhibitor cocktail
Thermo Fisher Scientific cat# 78442
Rapamycin LC laboratories cat# R-5000
Bafilomycin A1 LC laboratories cat# B-1080
Deposited Data
Full scans of western blot data and
original microscopy images
This paper Mendeley Data: https://doi.org/
10.17632/37tgjx44g4.1
Experimental Models: Cell Lines
Saos2 Tet-On DRAM1-myc tag This lab Crighton et al. 2006
Phoenix-AMPHO ATCC cat# CRL-3213
HEK293T ATCC cat# CRL-3216
3T3-L1 ATCC cat# CL-173
DRAM1 fl/fl MEF This article N/A
ATG7 fl/fl MEF This article N/A
ATG7 fl/fl DRAM1 KO MEF This article N/A




C57BL/6 mice Charles River Strain Code: 027
DRAM1fl/fl C57BL/6 mice This article N/A
DRAM1+/ C57BL/6 mice This article N/A
ATG7fl/fl C57BL/6 mice Komatsu et al. 2005 Komatsu et al. 2005
Oligonucleotides
See table for primer sequences N/A
Recombinant DNA
pBabe-puro Addgene cat# 1764
pLenti-puro Addgene cat# 39481
pLX304-SLC3A2 DNASU plasmid repository cat# HsCD00440549
pLX304-SLC1A5 DNASU plasmid repository cat# HsCD00436374
pLZRS-SLC3A2-RFP-GFP This article N/A
pLZRS- RFP-GFP-SLC3A2 This article N/A
psPAX2 Addgene cat# 12260
pMD2.G Addgene cat# 12259
p LAMP1-mRFP-Flag2X Addgene cat# 34611
pCMV6-mouse-DRAM1 Origene cat# MR220640
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pLentiCRISPR v2 Addgene cat# 52961
pLentiCRISPR v2 mouse DRAM1 #A This article N/A
pLentiCRISPR v2 mouse DRAM1 #B This article N/A
pLentiCRISPR v2 NTC1 This article N/A
pLentiCRISPR v2 NTC2 This article N/A
si/shRNA
Renilla shRNA (Non-targeting control) Mirimus LPE shRen.713
SLC1A5 shRNA Mirimus cat# SLC1A5_798
SLC1A5 shRNA Mirimus cat# SLC1A5_1062
SLC7A5 shRNA Mirimus cat# SLC7A5_1857
SLC7A5 shRNA Mirimus cat# SLC7A5_2000
ON-TARGETplus SLC1A5 smartpool siRNA GE Dharmacon cat# L-007429-00-0005
ON-TARGETplus SLC7A5 smartpool siRNA GE Dharmacon cat# L-041166-01-0005





Optimized CRISPR Design Feng Zhang Lab (MIT) http://zlab.bio/guide-design-resources
ZEN 2012 software Zeiss N/A
FlowJo software v.7.6.5 FlowJo N/A
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Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Kevin M. Ryan (k.ryan@
beatson.gla.ac.uk).
Reagents
D-Phenylalanine (Cat# P1751), L-Leucine methyl ester hydrochloride (Cat# L1002), L-g-glutamyl-p-nitoanilide (g-GPNA) (Cat#
G6133), L-Leucine (Cat# L8000), cycloheximide (Cat# C4859), puromycin (Cat# P9620), polybrene (Cat# H9268), doxycycline
(Cat# D9891), Protein A Sepharose beads (Cat# P9424), Anti-FLAG M2 Magnetic Beads (Cat# M8823), bicinchonic acid solution
(BCA) (Cat# B9643), Copper (II) sulfate solution (Cat# C2284), troglitazone (Cat# T2573), insulin (Cat# I9278), IBMX (Cat# I5879),
dexamethasone (Cat# D4902), Oil Red O solution (Cat# O1391), cOmplete protease inhibitor tablets (Cat# 4693124001) and Earle’s
Balanced Salt Solution (EBSS) (Cat# E2888) were obtained fromSigma-Aldrich. Fetal Bovin Serum (FBS) (Cat# 10270-106), penicillin/
streptomycin (Cat#15140-122), glutamine (Cat#25030-024), accutase (Cat#A11105-01), trypsin (Cat# 15090-046), Dulbecco’s
Modified Eagle Medium (DMEM) (Cat# 21969-035), LysoTracker Deep Red (cat#L12492) and 50X MEM amino acid solution (Cat#
11130-036) were purchased from Thermo Fisher Scientific. Rapamycin (Cat# R-5000) and Bafilomycin A1 (Cat# B-1080) were ob-
tained from LC laboratories.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
All in vivo experiments were performed using male C57BL/6 Dram-1 whole body knock-out or male C57BL/6 wild-type mice as
approved by the Glasgow University Animal Welfare and Ethical Review Body and in accordance with UK Home Office guidelines.
Mice were placed five per cage with free access to water and food. All experimental studies were started with animals at 10 weeks of
age, were randomized and did not involve blinding.
For in vitro studies, E13.5 embryos from wild-type mice containing two floxed Dram-1 alleles or E13.5 embryos from intercross of
DRAM1 hemizygous mice containing two floxed Atg7 alleles were used to generate Mouse Embryonic Fibroblasts (MEFs) with the
indicated genotypes prior to immortalization by serial passages. Experiments were also conducted in Saos2 TetOn-DRAM1 cells
(a derivative of Saos2 osteosarcoma cells, which can be obtained from ATCC (Cat# HTB-85) and the pre-adipocyte 3T3-L1
(ATCC, Cat# CL-173).Molecular Cell 76, 1–14.e1–e8, October 3, 2019 e3
Please cite this article in press as: Beaumatin et al., mTORC1 Activation Requires DRAM-1 by Facilitating Lysosomal Amino Acid Efflux, Molecular Cell
(2019), https://doi.org/10.1016/j.molcel.2019.07.021Cell culture
Cell lines were grown in DMEM supplemented by 10% FBS, 2 mM glutamine, 100 mg/mL streptomycin and 100 U/mL penicillin
(complete DMEM) at 37C 5%CO2. Saos2 TetOn-DRAM1 cells were either treated 24h with 1 mg/mL of doxycycline or left untreated
prior to perform experiments. For amino acid-induced mTOR re-activation experiments, cells were washed twice in PBS, starved in
EBSS containing or not 2 mM glutamine for 3 to 6 h and then incubated for the indicated times in EBSS containing specified treat-
ments. 3T3-L1 pre-adipocyte cell line was obtained from ATCC.
Retrovirus/ Lentivirus production and infection
Retrovirus and lentivirus were produced using Phoenix-AMPHO cells (ATCC, Cat#: CRL-3213) and HEK293T cells respectively using
calcium/phosphate transfection protocol. For lentivirus production, cells were transfected overnight with lentiviral, packaging and
envelope plasmids (pPAX2 and pVSVG). While for retrovirus production, Phoenix-AMPHO cells were only transfected with retroviral
constructs overnight. The following day, media were replaced by full DMEM containing 20% FBS for 48 h. Then media containing
viruses were collected, filtered (0.45 mm), supplemented with 4 mg/ml Polybrene and transferred to the recipient cells. In the mean-
time, HEK293T (or Phoenix-AMPHO) cells were kept in DMEM containing 20%FBS for an additional 24 h in order to proceed to a
second infection of recipient cells as described before. Finally, infected cells were selected with 1 mg/mL of puromycin for 10 days.
Constructs, shRNAs, siRNAs and CRISPR
SLC3A2-mRFP-eGFP andmRFP-eGFP-SLC3A2 were made by means of Gibson assembly using pLX304 SLC3A2 (DNASU plasmid
repository) plasmid and the previously described mRFP-eGFP-LC3 construct (1). pLX304 SLC1A5 plasmid was obtained from
DNASU plasmid repository. LAMP1-mRFP-Flag2X construct was obtained from Addgene (cat#34611) (2) and pCMV6-mouse-
DRAM1 (Myc-DDK-tagged) was obtained from Origene (cat# MR220640). shRNA against Renilla (Non-targeting control), SLC1A5
and SLC7A5 were provided by Mirimus (cat#SLC1A5_798, SLC1A5_1062, SLC7A5_1857, SLC7A5_2000). ON-TARGETplus Mouse
SLC1A5 smartpool siRNA (cat#L-056095-01-0005), ON-TARGETplus Mouse SLC7A5 smartpool siRNA (cat#L-041166-01-0005),
ON-TARGETplus Human SCAMP3 siRNA (cat#L-013442-00-0005) and non-targeting controls (NTCs, cat#D-001810-01-05,
D-001810-02-05, D-001810-03-05, D-001810-04-05) were obtained from GE Dharmacon.
The following sgRNA sequences were used in this study:
Mouse DRAM1 #A: CATCATCTCCTACGTGGTCG
Mouse DRAM1 #B: AGAGAGCACCGCGACCACGT
Non-targeting control #1 (NTC1): GTAGCGAACGTGTCCGGCGT (Wang et al., 2014)
Non-targeting control #2 (NTC2): GCTTGAGCACATACGCGAAT (Wang et al., 2014)Protein extraction and Immunoblotting
Cells were washed in ice cold PBS and lysed in 1% Triton X-100, 0.1% SDS, 50 mM HEPES pH7.5, 150 mM NaCl, 100 mM
NaF, 10 mM EDTA supplemented with HALT protease and phosphatase inhibitor cocktail (cat#87786,Thermo scientific). After
10 min centrifugation at 12000g at 4C, the concentration of solubilised proteins was determined with the bicinchoninic acid
assay (BCA). Protein samples were mixed with Laemmli loading buffer 4X (120 mM Tris pH6.8, 20% glycerol, 4% SDS, bro-
mophenol blue) and subjected to Tris-Glycine SDS-PAGE. Then proteins were transferred onto PVDF membranes and immu-
noblotted using different antibodies using 1/1000 dilution: Anti-Myc tag (cat#05-724, Millipore), ERK2 (cat#sc-154, Santa Cruz
biotechnology), SLC3A2 (cat#sc-9160, Santa Cruz biotechnology), LAMP2 (CD107b, cat#555803, BD PharMingen), SCAMP3
(cat# 26888-1-AP, Proteintech), Flag (cat#3165, Sigma-Aldrich). Anti- SLC1A5 (cat#5345), SLC7A5 (cat#5347), LC3B
(cat#2775), Phospho-p70 S6 Kinase (Thr-389, cat#9234), p70 S6 Kinase (cat#2708), Phospho-S6 Ribosomal protein (S235/
236, cat#4858), V5-Tag mAb (cat#13202), S6 Ribosomal protein (cat#2317), Phospho-4E-BP1 (Thr37/46, cat#2855), 4E-BP1
(cat#9644), Atg7 (cat#8558), Phospho-AKT (Thr308, cat#4056), AKT (cat#9272) PPARg (cat#2430), IRS1 (cat#2382), Phos-
pho-IRS1 (S636/639, cat#2388) and anti-mouse or anti-rabbit IgG HRP-linked (cat#7076S, cat#7074S, 1/5000) were from
Cell Signaling Technology. Loading controls (ERK2 and actin) as well as total S6K, total AKT, total S6, total 4E-BP1 were
probed following membrane stripping.
DRAM-1 immunoprecipitation
Saos2 TetOn-DRAM1 cells pre-treated with or without doxycycline were grown for 3-5 h in complete DMEM or EBSS. Cells were
washed in ice cold PBS and lysed in 1.2%CHAPS, 150mMNaCl, 50 mMHEPES pH 7.2 buffer supplemented byComplete protease
inhibitors (Roche) for 20 minutes. Solubilised proteins were collected after centrifugation at 10000g for 10 minutes. 1 mg of total
proteins, assessed by BCA, were mixed with 2 mg of anti-myc-tag antibody, incubated for 1 hour at 4C prior to incubation overnight
in presence of 50 mL of Protein A-Sepharose beads. Beads were washed 5 times using protein extraction buffer and elution was
performed using Laemmli loading buffer. Samples were subjected to SDS-PAGE, transferred on PVDFmembranes and immunoblot-
ted against indicated proteins.e4 Molecular Cell 76, 1–14.e1–e8, October 3, 2019
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For the TAP-Tag experiments, immunoprecipitated proteinswere eluted from the sepharaose beads using 1%SDS and separated by
SDS-PAGE, which was subsequently stained with Coomassie blue. Each gel lane was divided in 5 slices and digested according to a
procedure previously described (McGarry et al., 2016). Briefly, the bands were excised and washed twice with 50 mM ammonium
bicarbonate followed by 50 mM ammonium bicarbonate with 50% acetonitrile. Proteins were reduced using 10 mM DTT at 54C
for 30 minutes and alkylated with 55 mM iodoacetamide at room temperature for 45 minutes. Gel pieces were washed again with
50 mM ammonium bicarbonate and finally 50 mM ammonium bicarbonate with 50% acetonitrile. Gels were then dehydrated using
100% acetonitrile followed by drying in a speedvac. 5 mg/mL trypsin in 25 mM ammonium bicarbonate was added and incubated for
12 hours at 30C. Tryptic peptides were extracted from gel pieces with two 50% v/v acetonitrile/water washes and evaporated to
dryness prior to reconstituting in mobile phase for running.
For one of the replicates, the tryptic digest obtained was separated by nanoscale C18 reverse-phase liquid chromatography
(EASY-nLC II Thermo Fisher Scientific) coupled to a Linear Trap Quadrupole (LTQ) Orbitrap Velos mass spectrometer (Thermo Fisher
Scientific). Samples were loaded on a pre-column (C-18 Biosphere 5 mm, 120 A˚–200 mm 3 0.2 cm) for desalting, and subsequently
eluted, at a flow of 0.6 ml/min, into an analytical column (C-18 Biosphere 5 mm, 120 A˚–100 mm 3 15 cm).
The eluting peptide solutions were electrosprayed into the mass spectrometer via a nanoelectrospray ion source. General mass
spectrometric conditions were as follows: spray voltage, 2.1 kV, ion transfer tube temperature, 200C. The mass spectrometer was
operated in positive ion mode and used in data-dependent acquisition mode. A full scan (FT-MS) was acquired with resolution of
30,000 over mass range of 350–2000 amu, and the top ten most intense ions were selected for fragmentation using higher energy
collision dissociation (HCD). Fragmentation spectra in HCD were acquired in the FTMS analyzer at a resolution of 7500 in centroid
mode. Normalized collision energy used was 35. Former target ions selected for MS/MS were dynamically excluded for 60 s. The
‘lock mass’ function (lock mass = 445.120036 Da) was enabled for MS and MS/MS HCD scan modes.
For two other replicates, the tryptic digests were analyzed using an Ultimate 3000 nano-RP-LC (Dionex) coupled to a Q-Star XL
(Applied Biosystems, Concorde, Canada). Samples were loaded onto a PepMap100 trap column at a flow of 20 ml/min of RP-LC
buffer A (A: 5% ACN, 0.1% formic acid) and then separated using a PepMap C18 75-mm inner diameter3 15-cm analytical column.
Analyst software was used for data-dependant acquisition. The basic survey scan (1 s) from 400 to 1200 Da was followed by four
Enhanced Precursor Ion scans (1 s).
Data acquired with Q-star were exported from Analyst using the script Mascot.dll 1.6b23(Matrix Science, London, UK). Raw data
obtained from Orbitrap were processed with Raw2Msm MGF files were searched using Mascot (Matrix Science), querying UniProt
(UniProt Consortium, 2010) Homo sapiens plus an in-house database containing common proteomic contaminants and the
sequence of Streptavidin-FLAG–DRAM-1. Mascot was searched assuming the digestion enzyme trypsin allowing for two miscleav-
ages with a fragment ion mass tolerance of 0.1 Da and a parent ion tolerance of 35 ppm for Q-Star data and 10 ppm for Orbitrap data.
The iodoacetamide derivative of cysteine was specified inMascot as a fixedmodification. Oxidation of methionine and Protein N-ter-
minal acetylation were considered as variable modifications. Scaffold (version 4.3.2, Proteome Software) was used to summarize
MS/MS based peptide and protein identifications.
Metabolite Extraction
Cells were rapidly washed 3 times with chilled PBS. Intracellular metabolites were extracted, in triplicate, by adding a volume
equivalent to 1x106 cells/ml with extraction solution at 4C (methanol, acetonitrile, and water 5:3:2) and incubating the plate on a
rocking shaker for 5 minutes at 4C. The intracellular extract was centrifuged at 16100 g for 10 min at 4C and the supernatants
were transferred into HPLC vials and stored at 80C until LC-MS analysis.
LC-MS Analysis
A Q Exactive Orbitrap mass spectrometer (Thermo Scientific, Waltham, MA, USA) was used together with a Thermo Ultimate
3000 HPLC system. The HPLC setup consisted of a ZIC-pHILIC column (SeQuant, 150 3 2.1mm, 5 mm, Merck KGaA, Darmstadt,
Germany), with a ZIC-pHILIC guard column (SeQuant, 203 2.1mm) and an initial mobile phase of 20% 20mMammonium carbonate,
pH 9.4, and 80% acetonitrile. Cell and media extracts (5 ml) were injected and metabolites were separated over a 15 minute mobile
phase gradient, decreasing the acetonitrile content to 20%, at a flow rate of 200mL/min and a column temperature of 45C. The total
analysis time was 23 minutes. All metabolites were detected across a mass range of 75-1000 m/z using the Q Exactive mass
spectrometer at a resolution of 35000 (at 200 m/z), with electrospray (ESI) ionization and polarity switching to enable both positive
and negative ions to be determined in the same run. Temperature at the hESI source was 50C and spray voltage was 4500V for pos-
itive mode and/3500V for negative mode. Sheath gas was 25 arbitrary units and auxiliary gas 15 arbitrary units for both ionization
modes. A capillary temperature of 325Cwas used for both positive and negative ionization modes. Lock masses were used and the
mass accuracy obtained for all metabolites was below 5ppm. Data were acquired with Thermo Xcalibur software. The peak areas of
different metabolites were determined using Thermo TraceFinder software where metabolites were identified by the exact mass of
the singly charged ion and by known retention time on the HPLC column. Commercial standards of all metabolites detected had been
analyzed previously on this LC-MS system with the pHILIC column. Intracellular metabolites were normalized to protein content of
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Dram-1flox/flox MEF stably expressing Cre recombinase or a control vector and SLC3A2-mRFP-GFP or GFP-mRFP-SLC3A2 con-
structs were grown on glass coverslips for 48 h in regular DMEM and treated for 30 min in presence of LysoTracker Deep Red
(L12492, ThermoFisher) followed by 3 washes of 10min in regular DMEMmedia. Saos Tet-ON DRAM1-myc-his cells overexpressing
V5-tagged SLC1A5were grown on coverslips for 24hr in the presence or absence of doxycycline (1ug/ml), then treated for four h with
cycloheximide (100ug/ml) or anisomycin (10ug/ml). Cells were fixed in 4% paraformaldehyde, permeabilized in PBS, 1%BSA, 0.2%
Triton X-100 and stained for LAMP2 and V5 according to previously described protocol (Mrschtik et al., 2015). Coverslips were
mounted on slides using DAKOmounting medium containing DAPI and z stack images were taken by mean of a ZEISS 710 confocal
microscope with a 3 63 objective. Quantification of lysosome volume and the proportion of lysosomes containing SLC3A2 was un-
dertaken using Volocity 3D Imaging analysis software (Perkin-Elmer)
Lysosomal enrichment protocol
Saos2 TetOn-DRAM1 cells stably expressing LAMP1-mRFP-Flag2X construct were used for lysosomal fractionation assays according
to the previously describedprotocol (Zoncu et al., 2011). Briefly, cellswere either treated for 24hwith doxycyclin or left untreatedprior to
starvation containing glutamine or fed treatments for 5 h. Cells were first mechanically disrupted in fractionation buffer (50 mM KCl,
90 mM K gluconate, 1mM EGTA, 5mM MgCl2, 50 mM sucrose, 5mM glucose, 2.5mM ATP, 20 mM HEPES pH7.4 supplemented by
Complete protease inhibitors) before to centrifuge samples at 2000g at 4C for 10 min to obtain a postnuclear supernatant fraction
(PNS). PNS samples were then centrifuged 15min at 20600g at 4C prior to resuspension of pellets in fractionation buffer. These lyso-
somal enrich fractions were then incubatedwith 50 mL of anti-Flagmagnetic beads for 3h to overnight prior extensivewasheswith frac-
tionation buffer. Sampleswere differently treated according to the following experiment: For western blot analysis, proteinswere eluted
using Laemmli loading buffer. For amino acid lysosomal content assessments, beads were incubated in metabolites extraction buffer
(aqueous solutionof 50%methanol and30%acetonitrile) for 10min on ice, then sampleswerequickly centrifuged topellet beadsand to
collect buffer containing lysosomal metabolites. Samples were analyzed by means of LC-MS as described above.
Cell proliferation
Cells were plated at a density of 10000 cells per well in 6-well plates for Dram-1flox/flox MEF expressing cre recombinase or a control
vector while Atg7flox/flox Dram-1 knock-out or wild-type MEF were seeded at 20000 cells per well. Cell number was determined at the
specified time after cells have been washed in PBS, trypsinized, re-suspended and counted using Casy Innovatis cell counter.
Flow cytometric analysis
Dram-1flox/flox MEF stably expressing cre recombinase or a control vector were infected with retroviral particles encoding SLC3A2-
mRFP-GFP or GFP-mRFP-SLC3A2 constructs, followed by a week of antibiotic selection. Cells stably expressing the indicated
constructweregrownundercontrol conditionor starved for 3 h.Cellswere thenwashed inPBS, harvested usingAccutaseandanalyzed
for GFP and mRFPmean fluorescent intensities (MFI). For each condition and cell lines, GFPMFI were normalized to mRFPMFI. Each
ratio has been compared to the ratio from cells grown under control condition and expressing both DRAM1 and SLC3A2-mRFP-GFP.
In vitro insulin sensitivity
Cells were starved overnight from growth factors using DMEM containing glutamine, penicillin, streptomycin and 0.2% FBS. The
following day cells were treated with or without 5 nM insulin for 15 minutes. Cells were washed in ice cold PBS and protein extract
weremade as described previously. Where indicated, cells were pre-incubated inmedia containing 100 nM rapamycin for 4 h prior to
insulin treatments.
siRNA transfection
53 105Dram-1flox/floxMEF cells stably expressing cre recombinase or a control vector were plated in 10 cmdishes. The following day
cells are transfected with smart pool siRNAs using oligofectamine reagent. Briefly, 14.7 mL of 20 mMsiRNA resuspended in 53 siRNA
Buffer (GE Dharmacon) are mixed with 1085 mL of Optimem. A mix of 24 mL oligofectamine with 66 mL Opti-mem was incubated for
5-10 minutes at room temperature prior addition with the first siRNA mix. After 20 minutes incubation at room temperature, the mix
was added on cells for which media was previously replaced by 4.8 mL of Optimem. Cells were incubated overnight in presence of
siRNAs before replacing media by regular growing media for 24 h. Cells were then plated according to the desired experiment.
Animal experiments
Mice were fed a western diet (cat# T-5TJN-1810842 from TestDiet Limited) for the indicated time. Rapamycin was administrated
(4mg/kg) by intraperitoneal injection twice a week for the duration of the experiment. Cohorts of 10males for each group, andwith the
same age, were used to perform these experiments and mouse weights were measured weekly.
Mice were starved for 4 h prior to take basal glycemia readings from bleeding tails. Measurements were performed using Accu-
check test strips andmeter (Roche). Thenmice were given either 3g/kg glucose by oral gavage or 0.5U/kg of insulin by intraperitoneal
injections and blood glucose was assessed every 20 minutes for 2 h.e6 Molecular Cell 76, 1–14.e1–e8, October 3, 2019
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Mice were killed by CO2 mediated euthanasia before collecting different organs and tissues. Tissues were weighed prior to a min-
imum 24 h fixation step in 10% neutral-buffered formaldehyde. Paraffin-embedded sections were treated as previously described
(Sakamaki et al., 2017). Briefly, sections were successively dipped into xylene (5 min), 100% ethanol (2 3 1 min), 70% ethanol
(1 min) and deionized water for 5 min. Antigen retrieval was proceeded using Sodium citrate retrieval buffer pH 6 (cat#: TA-250-
PM1X, Thermo Fisher Scientific) at 98C for 25 min followed by 2 washes in Tris buffered saline and tween 20 (TBS-T). Sections
were then blocked (Peroxidase-blocking solution, cat#: S2023, Dako) prior incubation overnight at 4C with anti-Phospho AKT
(cat#4060, Cell Signaling), Phospho-AKT-T308 (cat#4056, Cell signaling), or Phospho-S6k1-T389 (cat#orb6617, Biorbyt). Sections
were then incubated with Labeled Polymer HRP anti-rabbit (cat#K4011, Dako). Incubation in DAB (3,30-diaminobenzidine tetrahydro-
chloride, cat#3468, Dako) was used to reveal staining. Sections weremounted and observed with a Zeiss Axio Scope.A1microscope
(Zeiss) and ZEN 2012 software.
Plasma adiponectin levels
Plasma adiponectin levels were assessed using ELISA kit from Abcam (cat#ab108785) according to manufacturer’s protocols.
Briefly, at the end of the HFD experiment, mice were killed by CO2-mediated euthanasia and blood samples were collected by direct
cardiac puncture. Samples were stored at 20C following 10 min centrifugation at 1500 x g and 4C. Each sample was analyzed in
duplicate using ELISA kits before to plot and to quantify the average of plasma adiponectin levels of each group.
3T3-L1 differentiation
1x105 cells were plated in each well of 6-well plates. Cells were grown with full DMEM media until they reached 100% confluence.
Media was then replaced and cells were kept in full DMEMmedia for 2 additional days. Then they were incubated in full DMEM sup-
plemented with 500 nM dexamethasone, 500 mM IBMX, 5 mg/mL insulin and various concentrations of troglitazone (0; 0.4; 4; 40 mM)
for 2 days. Themedia was replaced by full DMEMsupplemented only with 5 mg/mL insulin for 2more days. Cells were then kept under
full DMEM for an additional day before performing further experiments.
Oil Red O staining
Cells were washed in PBS prior to two successive incubations in 10% neutral-buffered formaldehyde for 10 and 60 min. Cells were
rinsed twice in deionised water and dried following 5 min incubation in 60% ethanol. Neutral lipids were then stained using Oil Red O
solution (Sigma) for 10 minutes. Excess of Oil Red O solution was eliminated by at least 5 washes with deionized water. Images were
taken, plateswere dried before solubilise staining using 100% isopropanol. Optical densities at 500 nmwavelengthwere read against
a solution of 100% isopropanol.
RT-qPCR
RNA were extracted from cells using RNeasy  Mini Kit (cat#74101, QIAGEN) and quantified using Nanodrop (ThermoFisher
scientific). cDNAs were produced using High Capacity RNA-to-cDNA kit (Appliedbiosystems from Thermo Fisher Scientific)
according to manufacturer’s protocol and qPCR were performed using DyNAmo HS SYBR Green qPCR Kit (cat#F-410, Thermo
Fisher Scientific). PCR was performed on a C1000 Thermal Cycler (CFX96 Real time system, BioRad) as follows: 3 min at 95 C,
followed by 40 cycles of 20 s at 95 C, 30 s at 58 C, 20 s at 72 C and a final 5 min at 72 C. mRNA quantifications were calculated
using DDCt method.
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All in vitro experiments were repeated at least three independent times and results are shown asmean ± SEM. All in vivo experiments
are shown as mean ± SEM or SD. Statistical significances were determined by two-tailed unpaired Student’s t test for two group
comparison and 2way ANOVA with Tukey or Dunnett for multiple group comparison. Results were considered statistically different
when p values < 0.05 (*); < 0.01 (**); < 0.001 (***). When required, no significance between results are mentioned as N.S.
DATA AND CODE AVAILABILITY
Full scans of western blot data and original microscopy images have been deposited in Mendeley Data (https://doi.org/10.17632/
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